Clinical Trial

Multimodal Analysis of Early Biomarkers of the Impacts of Perinatal Asphyxia

Study acronym: Neurobiom
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Current diagnostic methods rely primarily on clinical symptoms, supplemented by brain imaging and physiological tests. However, these signs of injury only become apparent once significant damage has occurred, thus delaying intervention and compromising the effectiveness of treatments. Therefore, there is a need to develop new markers to develop preventive measures for the consequences of perinatal asphyxia. The primary objective is to compare cognitive and motor development at 18 months in three populations (PA, at risk of PA, and Control) defined on the basis of clinical, biological, and neural criteria.
Trial Details
NCT Number NCT07702500
Lead Sponsor Centre Hospitalier Universitaire, Amiens
Conditions Neonate, Asphyxia, EEG, Eye Tracking, Biomarkers
Enrollment 280 participants
Start Date 2026-07
Primary Completion 2028-06 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-14